Kyowa Kirin Co., Ltd.
Clinical trials sponsored by Kyowa Kirin Co., Ltd., explained in plain language.
Now part of
Kyowa Kirin Co., Ltd.
4151
TOKYO
Pharmaceutical company focused on specialty medicines.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for japanese AML patients: experimental drug ziftomenib enters trial Results expected Mar 2027 (estimated)
- Experimental blood cancer drug KK2430 enters first human tests Results expected Apr 2027 (estimated)